National Cancer Institute; Notice of Closed Meeting, 57917 [2024-15579]
Download as PDF
Federal Register / Vol. 89, No. 136 / Tuesday, July 16, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Integrative Health; Notice of Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory
Council for Complementary and
Integrative Health.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend in
person and need special assistance,
such as sign language interpretation or
other reasonable accommodations,
should notify the Contact Person listed
below in advance of the meeting. The
open session can also be accessed at the
following NIH Videocast URL link
https://videocast.nih.gov
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Council for Complementary and Integrative
Health
Date: September 13, 2024.
Closed: 9:00 a.m. to 10:30 a.m.
Agenda: To review and evaluate grant
applications
Place: National Institutes of Health, 31
Center Drive, Building 31C/6th Floor,
Conference Room A&B, Bethesda, MD 20892,
In Person.
Open: 10:40 a.m. to 4:00 p.m.
Agenda: Reports and Updates about Recent
and Ongoing NCCIH Led or Involved
Activities by NCCIH staff and its Director.
Place: National Institutes of Health, 31
Center Drive, Building 31C 6th Floor,
Conference Room A&B, Bethesda, MD 20892,
In Person.
Contact Person: Martina Schmidt, PHD,
Director, Division of Extramural Activities,
National Center for Complementary &
Integrative Health, NIH, 6707 Democracy
Blvd., Suite 401, Bethesda, MD 20892, (301)
594–3456, schmidma@mail.nih.gov.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should be less than 700 words
in length, and should include the name,
email address, telephone number and
VerDate Sep<11>2014
16:55 Jul 15, 2024
Jkt 262001
when applicable, the business or
professional affiliation of the interested
person. Any member of the public may
submit written comments no later than
August 30th, 2024 (14 days before the
council meeting).
In the interest of security, NIH has
procedures at https://www.nih.gov/
about-nih/visitor-information/campusaccess-security for entrance into oncampus and off-campus facilities. All
visitor vehicles, including taxicabs,
hotel, and airport shuttles will be
inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal
facility will be asked to show one form
of identification (for example, a
government-issued photo ID, driver’s
license, or passport) and to state the
purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nccih.nih.gov/news/events/
advisory-council-88th-meeting, where
an agenda and any additional
information for the meeting will be
posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
Dated: July 11, 2024.
Victoria E. Townsend,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–15583 Filed 7–15–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
57917
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the
proposed research projects, the
disclosure of which would constitute a
clearly unwarranted invasion of
personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; JUN2024
Cycle 47 NExT SEP Committee Meeting.
Date: August 13, 2024.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To evaluate the NCI Experimental
Therapeutics Program Portfolio.
Place: National Institutes of Health, 9000
Rockville Pike, Building 31, Room 3A44,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Persons: Barbara Mroczkowski,
Ph.D., Executive Secretary, Discovery
Experimental Therapeutics Program,
National Cancer Institute, NIH, 31 Center
Drive, Room 3A44, Bethesda, Maryland
20817, 301–496–4291, mroczkoskib@
mail.nih.gov.
Toby Hecht, Ph.D., Executive Secretary,
Development Experimental Therapeutics
Program, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 3W110,
Rockville, Maryland 20850, 240–276–5683,
toby.hecht2@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: July 10, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of
Federal Advisory Committee Policy.
[FR Doc. 2024–15579 Filed 7–15–24; 8:45 am]
National Cancer Institute; Notice of
Closed Meeting
BILLING CODE 4140–01–P
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The purpose of this
meeting is to evaluate requests for
preclinical development resources for
potential new therapeutics for the
treatment of cancer. The outcome of the
evaluation will provide information to
internal NCI committees that will
decide whether NCI should support
requests and make available contract
resources for development of the
potential therapeutic to improve the
treatment of various forms of cancer.
The research proposals and the
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
Substance Abuse and Mental Health
Services Administration
Meeting of the Substance Abuse and
Mental Health Services Administration,
Center for Mental Health Services
National Advisory Council
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
Notice is hereby given of the
meeting on August 27, 2024, of the
Substance Abuse and Mental Health
Services Administration (SAMHSA),
Center for Mental Health Services
National Advisory Council (CMHS
NAC). The meeting is open to the public
SUMMARY:
E:\FR\FM\16JYN1.SGM
16JYN1
Agencies
[Federal Register Volume 89, Number 136 (Tuesday, July 16, 2024)]
[Notices]
[Page 57917]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-15579]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The purpose of this meeting is to evaluate requests
for preclinical development resources for potential new therapeutics
for the treatment of cancer. The outcome of the evaluation will provide
information to internal NCI committees that will decide whether NCI
should support requests and make available contract resources for
development of the potential therapeutic to improve the treatment of
various forms of cancer. The research proposals and the discussions
could disclose confidential trade secrets or commercial property such
as patentable material, and personal information concerning individuals
associated with the proposed research projects, the disclosure of which
would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel; JUN2024 Cycle 47 NExT SEP Committee Meeting.
Date: August 13, 2024.
Time: 10:00 a.m. to 2:00 p.m.
Agenda: To evaluate the NCI Experimental Therapeutics Program
Portfolio.
Place: National Institutes of Health, 9000 Rockville Pike,
Building 31, Room 3A44, Bethesda, Maryland 20892 (Virtual Meeting).
Contact Persons: Barbara Mroczkowski, Ph.D., Executive
Secretary, Discovery Experimental Therapeutics Program, National
Cancer Institute, NIH, 31 Center Drive, Room 3A44, Bethesda,
Maryland 20817, 301-496-4291, [email protected].
Toby Hecht, Ph.D., Executive Secretary, Development Experimental
Therapeutics Program, National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 3W110, Rockville, Maryland 20850, 240-276-5683,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: July 10, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee
Policy.
[FR Doc. 2024-15579 Filed 7-15-24; 8:45 am]
BILLING CODE 4140-01-P